FLUDARABİN-MELFALAN PROTOKOLÜ(AZALTILMIŞ YOĞUNLUKLU)(RIC)

Kaynaklar:

1- Oran B, Giralt S, Saliba R, et al. 2007 "Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan" Bio Blood and Marrow Transplantation".Volume 13, Issue 4, Pages 454-462

2- Bryant, A., I. Nivison-Smith, E. S. Pillai, et al. 2014. "Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients." Bone Marrow Transplant 49(1):17-23.

3- de Lima M, Anagnostopoulos A, Munsell M et al. 2004. "Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. Aug 1;104(3):865-72.

4- Kennedy G., J. Butler, S. Durrant et al. 2005. "Fludarabine/Melphalan Conditioning for Allogeneic Stem Cell Transplantation (SCT) in Elderly Patients with AML/MDS." Blood. 106:5410

5- Bhurani, D., M. Schifter and I. Kerridge. 2008. "Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand." Bone Marrow Transplant 42(8):547-550.

6- Giralt S, Thall PF, Khouri I et al. 2001. "Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.Blood. Feb 1;97(3):631-7.

7- Baron, F., M. Labopin, A. Peniket, et al. 2015. "Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation." Cancer 121(7):1048-1055.